tiprankstipranks
Trending News
More News >

RxSight backs FY25 revenue view $160M-$175M, consensus $170.34M

The company reiterated its 2025 full-year revenue, gross margin and operating expense guidance. Sees gross margin in the range of 71% to 73%, representing an implied increase of 30 basis points to 230 basis points compared to 2024; Operating expenses in the range of $150.0 million to $160.0 million, representing an implied increase of 10% to 18% compared to 2024; and Operating expenses include non-cash stock-based compensation expense in the range of $27.0 million to $30.0 million.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1